BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ifupinostat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ifupinostat\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07676175-3395@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ifupinostat: Phase 2 readout est. (NCT07676175)
DESCRIPTION:Ifupinostat\, phase 2.\nStudy: A Study of BEBT-908 in Combinati
 on With Chemotherapy in Patients With Previously Untreated Peripheral T-Ce
 ll Lymphoma (PTCL)\nEstimated primary completion: 31 January 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ifupinostat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07676175
URL:https://assetmemo.bio/drug/ifupinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854652-3395@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Ifupinostat: Phase 1 readout est. (NCT07854652)
DESCRIPTION:Ifupinostat\, phase 1.\nStudy: BEBT-908 in MEF2D-Rearranged Rel
 apsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leuk
 emia\nEstimated primary completion: 30 August 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ifupinostat#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07854652
URL:https://assetmemo.bio/drug/ifupinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07301138-3395@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ifupinostat: Phase 2 readout est. (NCT07301138)
DESCRIPTION:Ifupinostat\, phase 2.\nStudy: BEBT-908 Plus Chemotherapy Treat
 ment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Le
 ukemia Patients\nEstimated primary completion: 31 December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ifupinostat#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07301138
URL:https://assetmemo.bio/drug/ifupinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792253-3395@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ifupinostat: Phase 3 readout est. (NCT06792253)
DESCRIPTION:Ifupinostat\, phase 3\, Relapsed/Refractory Diffuse Large B-Cel
 l Lymphoma.\nStudy: Study Comparing BEBT-908 Combined With R to SOC for th
 e Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimate
 d primary completion: 31 December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ifupinostat#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06792253
URL:https://assetmemo.bio/drug/ifupinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
